ATR and neoplasm: Preclinical studies have demonstrated that BRG1 inactivation increases tumor invasiveness and enhances sensitivity to targeted agents inhibiting oxidative phosphorylation and drugs targeting EZH2, AURKA, ATR, CDK4, and CDK6.